Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
Status:
Completed
Trial end date:
2015-01-21
Target enrollment:
Participant gender:
Summary
The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin
in a pediatric population 3 months to <18 years old. Approximately 450 pediatric subjects
with a complicated intra-abdominal infection will be enrolled in the study and treated with
either moxifloxacin intravenously and orally if switched to oral therapy or ertapenem
(intravenously) and, if switched to oral therapy, amoxicillin/clavulanate.